---
title: 'MRD-guided zanubrutinib, venetoclax and obinutuzumab in relapsed CLL: primary
  endpoint analysis from the CLL2-BZAG trial'
date: '2025-01-30'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39883943/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20250131170634&v=2.18.0.post9+e462414
source: Blood
description: The phase 2 CLL2-BZAG trial tested a measurable residual disease (MRD)-guided
  combination treatment of zanubrutinib, venetoclax and obinutuzumab after an optional
  bendamustine debulking in patients with relapsed/refractory CLL. In total, 42 patients
  were enrolled and two patients with ≤2 induction cycles were excluded from the analysis
  population per protocol. Patients had a median of one prior therapy (range 1-5),
  18 patients (45%) had already received a BTK inhibitor (BTKi), seven ...
disable_comments: true
---
The phase 2 CLL2-BZAG trial tested a measurable residual disease (MRD)-guided combination treatment of zanubrutinib, venetoclax and obinutuzumab after an optional bendamustine debulking in patients with relapsed/refractory CLL. In total, 42 patients were enrolled and two patients with ≤2 induction cycles were excluded from the analysis population per protocol. Patients had a median of one prior therapy (range 1-5), 18 patients (45%) had already received a BTK inhibitor (BTKi), seven ...